Thursday, February 25, 2010
Systematic evidence reviews will examine the validity and utility of various health-related genomic tests (e.g., DNA, RNA, and proteomic tests; family health history tools; other health-related genomic services), including information on contextual factors and ethical, legal, and social issues. These evidence reviews will be conducted using the methods developed by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working GroupExternal Web Site Icon and CDC. Some of these reviews will be used by the EGAPP™ Working Group to make recommendation statements on the use of the genomic tests and other services.
The center will collaborate with CDC to develop brief evidence summaries (topic briefs) on the validity and utility of selected genomic applications and related issues.
Evidence reviews and topic briefs, along with recommendation statements and other resources, will be made publicly available in an online knowledge repository. This repository is being developed by NOPHG, NIH’s National Cancer InstituteExternal Web Site Icon, and the National Center for Biotechnology InformationExternal Web Site Icon of the National Library of MedicineExternal Web Site Icon and will be released later this year.
EvidenceUpdates: Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
Note: includes commentaries
The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 - financial news
"Since increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma, OGX-011 may have broad market potential to treat many cancer indications and disease stages."
Note: the NCCN website requires registration/password but is free. It is an excellent resource for ovarian cancer(s) as well as genetic syndrome guidelines.
Page 4 indicates changes over prior guidelines.
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
In the three-arm study, known as Gynecologic Oncology Group (GOG) 0218, women with newly diagnosed advanced ovarian cancer who already had surgery to remove as much of the tumor as possible were randomized to receive one of the following:
-- Arm 1: Placebo in combination with carboplatin and paclitaxel chemotherapy followed by placebo alone, for a total of up to 15 months of therapy
-- Arm 2: Avastin in combination with carboplatin and paclitaxel chemotherapy followed by placebo alone, for a total of up to 15 months of therapy
-- Arm 3: Avastin in combination with carboplatin and paclitaxel chemotherapy followed by the maintenance use of Avastin alone, for a total of up to 15 months of therapy.
The study showed that women who continued maintenance use of Avastin alone, after receiving Avastin in combination with chemotherapy (Arm 3), lived longer without the disease worsening compared to those who received chemotherapy alone. Women who received Avastin in combination with chemotherapy, but did not continue maintenance use of Avastin alone (Arm 2), did not live longer without the disease worsening compared to chemotherapy alone.
"It's up to a lobby group to bring democracy to discussions about changes to Ontario's hospitals.
That's because the provincial government refuses to do so, said Ontario Health Coalition executive director Natalie Mehra. Despite repeated requests to the Ministry of Health, asking that its public Rural and Northern Health Care Panel hold public consultations, Mehra said the government has "refused to hold public consultations."
She said the government's panel will only be consulting with select organizations including Ontario Hospital Association, the Ontario Medical Association, Registered Nurses Association of Ontario and an emergency medical service organization.
"There's not a single patient group, no municipality, no seniors group, or advocacy groups, or public interest groups, nobody," she said in an interview Tuesday....."
"Eighteen pregnancies (nine spontaneous) were observed in 14 patients."
Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.
"These data suggest that accumulated alterations of p27(Kip1)-interacting proteins may accelerate the development of CCAs regardless of their carcinogenetic pathways, but that tumor cells in the CCAF-associated pathway appear to show slower cell-cycle progression than those in the endometriosis-associated pathway, possibly accounting for the distinct clinicopathological features of the two CCA subtypes."
Histology and clinical characteristics of primary ovarian tumors. (serous, endometrioid, clear cell - CA125 levels, menopausal status,patient age)
Epithelial ovarian carcinoma is a significant cause of cancer mortality in women worldwide and in the United States. Epithelial ovarian cancer comprises several histological subtypes, each with distinct clinical and molecular characteristics. The natural history of this heterogeneous disease, including the cell types of origin, is poorly understood.
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
"An unacceptably high proportion of pathologic examinations did not adequately examine ovaries and fallopian tubes obtained at RRSO."